Is clozapine antisuicidal?

Expert Review of Neurotherapeutics

Volumn 4, Issue 2, 2004, Pages 187-190

  Kerwin, Robert W ^a   Bolonna, Anusha A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Atypical antipsychotic; Clozapine; Schizophrenia; Suicide

Indexed keywords

CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

CLINICAL TRIAL; HUMAN; MORTALITY; REVIEW; SCHIZOPHRENIA; SUICIDE;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; HUMANS; RISK FACTORS; SCHIZOPHRENIA; SUICIDE;

EID: 1542374115     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.2.187     Document Type: Review

References (29)

1. Appleby L. Safer services: national confidential inquiry into suicide and homicide by people with mental illness. Department of Health, London, UK (1999).
2. Meltzer HY, Fatemi H. Suicide in schizophrenia: the effect of clozapine. Clin. Neuropharmacol. 18(Suppl.), S18-S24 (1995).
3. Nyman AK, Jonsson H. Patterns of self-destructive behaviour in schizophrenia. Acta Psychiatr. Scand. 73(3), 252-262 (1986).
4. Addington DE, Addington JM. Attempted suicide and depression in schizophrenia. Acta Psychiatr. Scand. 85(4), 288-291 (1992).
5. Modestin J, Zarro I, Waldvogel D. A study of suicide in schizophrenic inpatients. Br. J. Psychiatry 160, 398-401 (1992).
6. Axelsson R, Lagerkvist-Briggs M. Factors predicting suicide in psychotic patients. Eur. Arch. Psychiatry Clin. Neurosci. 241(5), 259-266 (1992).
7. Caldwell CB, Gottesman II. Schizophrenia - a high-risk factor for suicide: clues to risk reduction. Suicide Life Threat Behav. 22(4), 479-493 (1992).
8. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br. J. Psychiatry 175, 576-580 (1999).
9. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol. Bull. 24(1), 62-67 (1988).
10. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry 152(2), 183-190 (1995). First published hint that clozapine may be specifically antisuicidal in a mirror image design.
11. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 8, 671-677 (1997). Very large epidemiological cohort able to look at completed suicides confirming the strong effect of clozapine.
12. Reinstein MJ, Chasonov MA, Colombo KD, Jones LE, Sonnenberg JG. Reduction in suicide inpatients with schizophrenia receiving clozapine. Clin. Drug Invest. 22, 341-346 (2002).
13. Sernyak MJ, Desai R, Stolar M, Rosenheck R. Impact of clozapine on completed suicide. Am. J. Psychiatry 158, 931-937 (2001).
14. Barnes RE, Kerwin RW. Mortality and sudden death in schizophrenia. In: Cardiovascular Risk Associated with Schizophrenia and its Treatment. Camm J (Ed.). Galliard Healthcare Communications, London, UK, 7-23 (2003).
15. Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60(1), 82-91 (2003). Definitive randomized, control trial confirming the superiority of clozapine over olanzapine.
16. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials; an analysis of the Food and Drug Administration database. Am J Psychiatry 158(9), 1449-1454 (2001).
17. Beasley CM, Sayler ME, Kiesler GM et al. The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia. Schizophr. Res. 29, 28 (1998).
18. Glazer WM. Formulary decisions and health economics. J. Clin. Psychiatry 59(Suppl. 19), 23-29 (1998).
19. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol. Drug Saf. 12(5), 423-424 (2003).
20. Sturkenboom MC, Picelli G, Moore N. Mortality during use of sertindole and other antipsychotics in The Netherlands and Belgium. Pharmacoepidemiol. Drug Saf. 10(Suppl. 1), S116 (2001).
21. Department of Health. Saving lives: our healthier nation (Cm 4386). Stationery Office, London, UK (1999).
22. Duggan A, Warner J, Knapp M, Kerwin R. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br. J. Psychiatry 182, 505-508 (2003). First ever modeling exercise to calculate the number of lives saved for the extended use of clozapine.
23. Meltzer HY, Cola P, Way L et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am. J. Psychiatry 150(11), 1630-1638 (1993).
24. Anderson C, Connelly J, Johnstone EC, Owens DG. Disabilities and circumstances of schizophrenic patients - a follow-up study. V: cause of death. Br. J. Psychiatry 159(Suppl. 13), 30-33 (1991).
25. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can. J. Psychiatry 36(4), 239-245 (1991).
26. Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr. Scand. 81(3), 231-235 (1990).
27. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br. J. Psychiatry 163, 183-189 (1993).
28. Black DW, Fisher R. Mortality in DSM-III-R schizophrenia. Schizophr. Res. 7, 109-116 (1992).
29. Tsoi WF, Wong KE. A 15-year follow-up study of Chinese schizophrenic patients. Acta Psychiatr. Scand. 84(3), 217-220 (1991).